146results about "Microcarriers" patented technology

The invention discloses application of a 3D hypoxia mesenchymal stem cell derived exosome preparation in preparation of an immune cell proliferation inhibitor or a medicine for treating acute myocardial infarction, belongs to the technical field of biology, and solves the problems of low cell survival rate and immunological rejection in application of a cell treatment method in the prior art. The 3D hypoxia mesenchymal stem cell derived exosome is used as a medium for treating acute myocardial infarction, and the problem of immunological rejection can be solved.

Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and / or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and / or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity assays.

The embodiment of the invention discloses a method for constructing a cartilage micro-tissue by compounding an extracellular matrix with a vascular matrix component and application. The method comprises the following steps: preparing a porcine decellularized cartilage extracellular matrix; generating a cartilage extracellular matrix suspension; carrying out screening treatment on the cartilage extracellular matrix suspension; preparing a porcine acellular cartilage extracellular matrix microcarrier; preparing a target suspension of a common system from the porcine acellular cartilage extracellular matrix microcarrier and vascular matrix component cells, and transferring the target suspension to a bionic floating microenvironment of a shaker bioreactor for dynamic culture; carrying out culture treatment on the porcine acellular cartilage extracellular matrix microcarrier; and taking out the cell-loaded porcine decellularized cartilage extracellular matrix microcarrier from the cultured and treated porcine decellularized cartilage extracellular matrix microcarrier as the constructed cartilage micro-tissue. According to the embodiment, the condition of secondary injury to a user can be improved and reduced, the repairing effect is improved, and the adaptability of the constructed cartilage micro-tissue is improved.

The invention relates to a preparation method of a Vero cell influenza virus vaccine, and belongs to the technical field of virus culture. In the culture of the influenza virus, red algae protein and soybean protein hydrolysate are added into a culture medium at the same time, the red algae protein and soybean protein hydrolysate are subjected to low-temperature ammonium sulfate precipitation and PD-10 desalination column purification, natural conformation is kept, integrin-FAK-Src and IGF-1R signal channels can be activated, and cell adhesion and proliferation are promoted; the latter contains soybean protein isolate, polysaccharide and RGD motif peptide, and can form an adhesion film on a substrate and mediate adhesion through integrin. According to the invention, the Vero cells and the recombinant plasmid are combined to improve cell adherence, metabolic homeostasis and oxidation resistance, so that the Vero cells grow at high density and efficiently replicate influenza viruses under a serum-free condition, the virus titer (TCID50) reaches 8.5 log10 / mL, and the Vero cells and the recombinant plasmid are suitable for industrial vaccine production.

The invention discloses a preparation method of a micron-sized cell-matrix co-polymer biological material. The preparation method comprises the following steps: firstly, inducing SHED cells in an ultra-low adsorption plate by using an alpha-MEM culture medium containing serum, GlutaMAXI, vitamin C and the like to form micron-sized spheres (SHED spheres); secondly, taking human dentin, and carrying out mechanical crushing, EDTA (Ethylene Diamine Tetraacetic Acid) demineralization, grinding and sterilization to prepare 1-100 microns of dentin matrix particles (DDMPs); and finally, by taking the GelMA hydrogel as a carrier, entrapping SHED spphere and DDMPs, and carrying out 405nm photo-crosslinking for 30 seconds to form the hydrogel. The co-polymer can significantly promote angiogenesis and osteogenesis coupling regeneration in a bone defect model, and is suitable for oral cavity and cranio-maxillofacial bone repair.

A cell culture microcarrier bead is proposed. The microcarrier bead comprises a bead body having its surface flecked with plasmonic nanoparticles. In a second aspect, the invention relates to a cell culture reactor, containing a cell culture medium and the proposed microcarrier beads. A third aspect of the invention concerns a method for observing living cells on such microcarrier beads. Yet a further aspect of the invention relates to a method for packing nanoparticles on a carrier body.

According to the present invention, the present invention relates to a polymer microparticle having a core-shell structure, which comprises: a core comprising a first biocompatible polymer, a metal ion, and an organic crosslinker having one or more reactive functional groups; and a shell surrounding all or a part of the core and comprising a second biocompatible polymer, a metal ion, and an organic crosslinker having one or more reactive functional groups; and a cell attachment-inducing layer formed on the surface of the polymer microparticle; and a microcarrier, a cell complex comprising the same, a medical composition, a cosmetic composition, a medical product, and a cosmetic product.

The invention relates to a polylactic acid microcarrier and a method for cell amplification by using the polylactic acid microcarrier. The preparation method disclosed by the invention is simple and convenient to operate, the prepared polylactic acid microcarrier is uniform in particle size and pore size distribution, the microcarrier is subjected to surface retreatment, more active sites are provided for cell adhesion, a three-dimensional matrix environment closer to a body is provided, cell amplification is facilitated, the dryness and differentiation potential of stem cells are maintained, and the preparation method is suitable for large-scale popularization and application. And the microcarrier can be repeatedly used, so that the use cost is reduced.

A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided.

The present invention relates to methods for extracting stem cells from a tissue, and culturing, expanding and / or recovering these stem cells, with at most one step of exposure to a protease. The present invention also relates to stem cells obtained by these methods, and compositions comprising thereof, and their applications.

The present invention relates to a method for reducing aggregation in a cell cluster-based cell culture system, such as a microcarrier-based or a spheroid-based cell culture system.

The invention discloses a microcarrier with the surface modified with a herpes virus receptor and application of the microcarrier, and relates to the technical field of animal virology technologies and veterinary biological products. The microcarrier is composed of a microcarrier matrix and herpes virus specific receptor protein fixed to the surface of the microcarrier matrix through chemical coupling; the microcarrier matrix is made of a biocompatible material, and the particle size of the microcarrier matrix is 1-10 [mu] m; the herpes virus specific receptor protein is an extracellular region fragment of a nectin-1 receptor. The method has the advantages that the virus infection efficiency and the virus yield are remarkably improved by accurately regulating and controlling the particle size of the microcarrier and adopting a receptor fixing technology, and the performance is particularly excellent under the condition of low infection complex number; meanwhile, the process is greatly simplified, and the pollution risk is reduced; and the method can be widely applied to herpes virus production, vaccine preparation and difficult-to-culture virus amplification by replacing receptors, and has a wide application prospect.

The present invention relates to a method for the preparation of an assembly of cells and microrobots comprising (a) preparing a suspension of cells and microrobots, wherein the microrobots comprises an alginate, collagen, fibrin, hyaluronic acid / collagen, polyacrylamide, or polyethylene glycol hydrogel capsule, wherein the alginate is conjugated to cell adhesive peptides, and (b) incubating the suspension of (a) to allow the microrobots to form an assembly with the cells via the binding of the cell adhesive peptides to the cells, wherein step (b) and preferably steps (a) and (b) are performed in a conic microcentrifuge tube with a rounded bottom without corners and edges.

The present disclosure provides processes for genetically engineering T cells, such as primary CD4+ T cells and / or CD8+ T cells, for use in cell therapy that does not involve expanding the cells. In particular aspects, the provided processes successfully generate compositions of engineered T cells, such as containing populations of engineered T cells, that express a chimeric antigen receptor (CAR) within a shortened amount of time as compared to alternative engineering processes, such as processes that involve expanding the cells. In certain aspects, the provided processes successfully generate a composition of engineered T cells suitable for use in cell therapy within 4 days from when the process to stimulate or activate the cells is initiated. In some aspects, the resulting engineered cell compositions are composed of cell population that are less differentiated, less exhausted, and more potent than engineered T cell compositions generated by other means, such as by processes that involve expanding the cells. Also provided are compositions of T cells generated by the provided methods and their uses for treating subjects.

The application discloses an engineered umbilical cord stem cell and application thereof in preparation of anti-aging drugs and medical beauty products. The application constructs an engineered cell system with high anti-aging function by designing a fusion polypeptide TAT-SIRT1-SOD (SEQ ID NO: 1) and an anti-p16INK4a monoclonal antibody (mAb-p16) to cooperatively modify the umbilical cord stem cell, and combining a 3D dynamic culture technology. The fusion polypeptide is mediated to cross the membrane by a TAT cell-penetrating peptide, activates SIRT1 and removes mitochondrial ROS; the mAb-p16 is specifically combined with p16INK4a on the surface of a senescent cell, and removes the senescent cell through an ADCC effect. Experiments show that the engineered umbilical cord stem cell can increase the removal rate of the senescent cell by 86.1%, increase the SOD activity by 300%, significantly inhibit the secretion of an inflammatory factor IL-6, and increase the skin collagen density by 148% and reduce the wrinkle depth by 67% in an animal model. The application provides a novel and efficient technical scheme for anti-aging drugs and medical beauty products.

The present invention provides a biomaterial for immunomodulation comprising aggregates of phenotypically stabilized cells. Said biomaterial is meant to be preferentially administered in a limited location and provides immunomodulation for preventive or therapeutic purposes.It is also part of the present invention the process for production of the mentioned biomaterial and uses thereof. More specifically, the biomaterial for immunomodulation herein disclosed adds benefit in contexts of transplantation, chronic inflammation, autoimmune diseases, acute inflammation, cancer treatment, or in injured tissue regeneration.

Provided herein are methods for culturing animal cells in a culture medium comprising a culture ingredient that is composed of or produced by yeast. In particular, the culture ingredient comprises, consists essentially of or, or consists of, inactivated yeast. Also provided herein is use of inactivated yeast as a matrix, support, carrier or microcarrier for growing meat cells in in vitro culture.

The present disclosure relates to a stem cell-drug carrier including a melatonin-containing drug carrier and a stem cell, and more particularly, to a use of the stem cell for the treatment of intestinal epithelial damage disease and inflammatory bowel disease. According to the present disclosure, it was confirmed that the stem cell-drug carrier continuously released PGE2 and had excellent revival stem cell induction ability. This means that the stem cell-drug carrier of the present disclosure has an excellent intestinal epithelium regeneration effect, and the stem cell-drug carrier of the present disclosure can be used in various fields of treatment of intestinal damage disease and inflammatory bowel disease.

To provide materials and methods for the preparation of blood products.SOLUTION: In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.SELECTED DRAWING: None

The present invention provides a method for expanding anti-tumor T cells comprising the steps of: a) providing a phagocyzable particle having one or more tumor neoantigen constructs in intimate association therewith wherein the tumor neoantigen constructs comprise an amino acid sequence comprising at least one mutant amino acid known or suspected of being associated with cancer in a subject, or a mutated or non-mutated amino acid sequence known or suspected of expression in cancer cells of the subject; b) providing a living antigen presenting cell; c) contacting the particles with the antigen presenting cells in vitro under conditions that allow the antigen presenting cells to phagocytize the particles; d) providing a T cell sample comprising live T cells from the subject; e) contacting the T cell sample with the antigen presenting cells in in vitro contact with the particles under conditions allowing specific activation of the anti-tumor T cells in response to the antigen presented by the antigen presenting cells. The invention also provides tumor neoantigen constructs as defined in the specification.

The invention discloses a method for large-scale cryopreservation of animal cells. The method comprises the following steps: carrying out first-stage amplification on to-be-preserved cells under the support of matrigel; performing second-stage amplification on the to-be-preserved cells subjected to the first-stage amplification under the support of a microcarrier; mixing the to-be-preserved cells with a serum-free cryopreservation solution to prepare a micro-capsule suspension; and putting the microcapsule suspension into a cryopreservation container to carry out cryopreservation. According to the invention, through amplification of two stages, the to-be-preserved cells have reached a high density of 109 orders of magnitude before cryopreservation, a re-amplification link in a cell recovery stage can be greatly shortened, and the to-be-preserved cells are subjected to microencapsulation through the micro-fluidic chip and then cryopreserved, so that physical protection is given to the to-be-preserved cells; the damage of ice crystals in the cryopreservation process is reduced, the survival rate after resuscitation is improved, and the microencapsulated cells can also be directly subcultured, so that the resuscitation operation is simplified; according to the cell cryopreservation device, the cryopreservation container with a large volume is used, so that the cost of cell cryopreservation is reduced.

A substrate for culturing cells that comprises a modified prolamin having a net positive charge is provided. The modified prolamin may be a prolamin that has been modified through amidation or esterification, such as the addition of a methyl-ester group or an ethanolamine group. The modified prolamin is animal-free may be food-grade and / or may be free of cross-linkers. The modified prolamin may be in a coating that can be applied to a surface for culturing adherent cells, such as a microcarrier (e.g., beads) or well plates. Substrates coated with the modified prolamin are able to support cell expansion and can be used for food-grade applications such as cultured meat.

The invention relates to bio-ink, microspheres for bio-ink, and preparation methods of the bio-ink and the microspheres. The bio-ink comprises: a microsphere comprising a methacrylated gelatin and a first conductive polymer, the microsphere optionally comprising a first cell; a hydrogel comprising a methacrylated gelatin and a second conductive polymer, the hydrogel optionally comprising second cells, the microspheres having pores. The bio-ink provided by the invention has good biocompatibility, conductivity, rheological property and mechanical property, and can promote interaction among biological materials.

The present invention relates to a stem cell-drug delivery system comprising a melatonin-containing drug carrier and stem cells, and, more specifically, to a use of the stem cells for treating intestinal epithelial damage diseases and inflammatory bowel disease. It has been identified that the stem cell-drug delivery system according to the present invention continuously releases PGE2 and has an excellent ability to induce revival stem cells. Therefore, the intestinal epithelial cell regeneration effect thereof is excellent, and thus the stem cell-drug delivery system of the present invention can be variously used in the fields of treating intestinal damage diseases and inflammatory bowel disease.

The present disclosure provides processes for genetically engineering T cells, such as primary CD4+ T cells and / or CD8+ T cells, for use in cell therapy that does not involve expanding the cells. In particular aspects, the provided processes successfully generate compositions of engineered T cells, such as containing populations of engineered T cells, that express a chimeric antigen receptor (CAR) within a shortened amount of time as compared to alternative engineering processes, such as processes that involve expanding the cells. In certain aspects, the provided processes successfully generate a composition of engineered T cells suitable for use in cell therapy within 4 days from when the process to stimulate or activate the cells is initiated. In some aspects, the resulting engineered cell compositions are composed of cell population that are less differentiated, less exhausted, and more potent than engineered T cell compositions generated by other means, such as by processes that involve expanding the cells. Also provided are compositions of T cells generated by the provided methods and their uses for treating subjects.

A process for the production of a composition comprising extracellular vesicles, comprising the following steps:  Culturing of stem cells, preferably adipose-derived stem cells;  Differentiating the stem cells, preferably osteogenically or chondrogenically differentiating the stem cells;  Adding of a particulate material, preferably gelatin beads, to obtain a scaffold-free multi-dimensional cell culture;  Collecting the liquid containing extracellular vesicles from the scaffold-free multi-dimensional cell culture;  Subjecting the liquid containing the extracellular vesicles to tangential flow filtration (TFF). The obtained composition comprising extracellular vesicles is useful for the treatment of cancer, in particular for the induction of apoptosis in cancer cells.

The present disclosure relates to a microcarrier for cell culture comprising polystyrene-based particles, a method for preparing the microcarrier for cell culture, and a cell culture composition using the same.

A method for forming microcarriers includes forming liquid drops from a sol-gel solution; depositing the drops in the form of a liquid on a first, preferably hydrophobic support; deforming the drops deposited on the first support; solidifying the drops by gelling and drying, so as to form solid microcarriers; and extracting the solidified microcarriers from the first support.

The present invention relates to a method for preparing a nanofibrous scaffold and use of the same for promoting cell culturing. In particular, the nanofibrous scaffold comprises crosslinked cellulose nanofibers which yield a continuous microcarrier material for use in industrial scale cell culturing setups.

The present application relates to a kind of microcarrier and its application, the microcarrier has three-dimensional structure, the microcarrier has shell and inside is hollow or solid, the shell outer wall is uneven and has multiple concave points.This microcarrier improves the permeability of traditional microcarrier, is conducive to the material exchange between cell and external environment, improves cell survival rate, provides good mechanical protection for cell proliferation and constructs good three-dimensional structure for cell growth, realizes the friendly connection of cell, is conducive to the large-scale expansion of cell in limited space, and maintains the stability of cell physicochemical properties in long-term culture.